JCO:诊断结直肠癌后才使用阿司匹林,也能改善生存率(附MedSci点评)

2016-06-20 Mechront 译 MedSci原创

根据在挪威进行的一项回顾性队列研究结果,诊断结直肠癌后开始服用阿司匹林,可改善患者的总生存率(OS)和肿瘤特异性生存率。 奥斯陆生物技术中心主任、挪威分子医学中心以及奥斯陆大学的医学教授Kjetil Taskén博士和同事从挪威癌症登记处和挪威处方数据库,确定了23162例(女性,n = 11486)在2004-2011年被诊断为结直肠癌的患者。研究人群中,26.3%(n = 6102,平均

根据在挪威进行的一项回顾性队列研究结果,诊断结直肠癌后开始服用阿司匹林,可改善患者的总生存率(OS)和肿瘤特异性生存率。 奥斯陆生物技术中心主任、挪威分子医学中心以及奥斯陆大学的医学教授Kjetil Taskén博士和同事从挪威癌症登记处和挪威处方数据库,确定了23162例(女性,n = 11486)在2004-2011年被诊断为结直肠癌的患者。研究人群中,26.3%(n = 6102,平均年龄,74岁)的患者在诊断后暴露于阿司匹林(定义为癌症诊断后接受阿司匹林处方超过6个月)。该研究以OS和癌特异性生存率为主要研究终点。中位数随访3年。 在阿司匹林队列中,32.9%(n = 2071)的患者死亡,19%(n = 1158)的患者死于结直肠癌。诊断结直肠癌后非阿司匹林暴露组的数据则分别为42.3%(n = 7218)和31.5%(n = 5735)。多变量分析表明,暴露阿司匹林能改善癌症特异性生存率(HR = 0.85; 95% CI, 0.79-0.92)和OS(HR = 0.95, 95% CI, 0.9-1.01)。 接着研究人员将参与者分为三个亚组:非阿司匹林暴露组(n=

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891277, encodeId=300618912e799, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 29 08:29:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128500, encodeId=366512850034, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 09:39:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256541, encodeId=c636125654198, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452804, encodeId=fe2d1452804e9, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606953, encodeId=78e216069531a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=)]
    2017-03-29 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891277, encodeId=300618912e799, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 29 08:29:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128500, encodeId=366512850034, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 09:39:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256541, encodeId=c636125654198, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452804, encodeId=fe2d1452804e9, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606953, encodeId=78e216069531a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=)]
    2016-09-16 1e10c84am36(暂无匿称)

    不错哦,会学到很多

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891277, encodeId=300618912e799, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 29 08:29:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128500, encodeId=366512850034, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 09:39:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256541, encodeId=c636125654198, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452804, encodeId=fe2d1452804e9, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606953, encodeId=78e216069531a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891277, encodeId=300618912e799, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 29 08:29:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128500, encodeId=366512850034, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 09:39:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256541, encodeId=c636125654198, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452804, encodeId=fe2d1452804e9, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606953, encodeId=78e216069531a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1891277, encodeId=300618912e799, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed Mar 29 08:29:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=128500, encodeId=366512850034, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 09:39:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256541, encodeId=c636125654198, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452804, encodeId=fe2d1452804e9, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606953, encodeId=78e216069531a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Jun 22 01:29:00 CST 2016, time=2016-06-22, status=1, ipAttribution=)]

相关资讯

ASCO 2016:Wnt信号通路或在年轻结直肠癌患者发病中扮演重要角色

当增加筛查持续降低结直肠癌总体发病率的同时,50岁以下结直肠癌患者的发病率却一直在增加,而且结直肠癌在年轻患者中也越来越成为一种常见的恶性疾病。近日,来自科罗拉多大学医学院的研究人员就揭示了在年轻患者中结直肠癌危险性增加的一种可能性原因,年轻患者和老年患者机体中往往存在很多相同的遗传改变,而年轻患者机体中更容易出现基因改变,比如Wnt信号通路发生改变,这种信号通路可以驱动癌症干细胞存活、生长及增殖

ASCO 2016:转移性结直肠癌患者BMI越高,生存越好?

ASCO年会上的一项荟萃分析结果显示,与正常体重患者相比,超重和肥胖的转移性结直肠癌患者有更长的OS。此外BMI<18.5的患者经历了显着恶化的OS和PFS。来自法国Avicenne医院的Thomas Aparicio博士说:“我们的分析结果证实了先前的研究结果,肥胖提高转移性结直肠癌患者的生存。值得注意的是,贝伐单抗对肥胖和非肥胖患者的有效性是一致的,但改善肥胖患者预后的原因仍然是未知的;有人认

Am J Clin Nutr:饮酒与结直肠癌生存研究

先前关于酒精摄入量和结直肠癌预后的相关性研究取得了不一致的结果。因此研究者进行了一项基于人群的队列研究,探究诊断结直肠癌(CRC)前一年饮酒情况和寿命的关系。该研究在2003-2010年公安如了3121名CRC患者,研究者获取了患者的社会人口学、生活方式因素、药物和并发症等情况。在中位数随访4.8年的时间里记录了患者的癌症复发、生命状态和死亡原因等。研究者使用Cox比例风险回归评估了酒精摄入量和整

Br J Surg:切除卵巢会增加结直肠癌风险

结直肠癌的发展受激素因素的影响。卵巢切除术会改变性激素的内源性水平,但对结直肠癌风险的影响尚不清楚。本研究的目的是评估因良性病变行卵巢切除术后患结直肠癌的风险。该研究纳入了1995-2011年间行卵巢切除术的女性,与一般人群相比,计算了结直肠癌风险的标准化发病率(SIRs)和95%置信区间。并对单侧和双侧卵巢切除术、以及不规范子宫切除术(是否摘除卵巢)进行分层研究。使用Cox比例风险回归模型计算三